Lung Cancer News

An analysis of global online conversations among health care professionals on social media in February showed an overarching sense of enthusiasm about FDA approval of the first cellular therapy to treat unresectable or metastatic melanoma.

Black patients and those with interstitial fibrosis or advanced-stage disease had a higher risk for developing clinically detectable postoperative venous thromboembolism after pulmonary resection for lung cancer, study results showed.

Most oncologists treating non-small cell lung cancer reported more research into immunotherapy treatments, patients with comorbidities and biomarker testing will be vital to improving care, according to results of a nationwide survey.

The FDA approved osimertinib plus platinum-based chemotherapy for certain adults with locally advanced or metastatic non-small cell lung cancer.

Invasive procedures aimed at clearing up imaging abnormalities found on lung cancer screening scans occurred infrequently, according to results published in CHEST.

Circulating tumor DNA analyses can be used as an early marker of immunotherapy response, according to data published in Nature Medicine.

Patients who underwent cancer surgery had an increased risk for venous thromboembolism for up to 1 year after the procedure, results from a retrospective study published in JAMA Network Open showed.

Positive associations were found between smoking and risk of developing ALS, with the strongest correlation found among those who actively smoked, according to research from Tobacco Induced Diseases.

Next-generation technologies and diagnostic tests offer the promise of improved cancer care, but they also present challenges related to ensuring widespread access to these innovations.

The proportion of individuals with newly diagnosed cancer who lacked insurance in the U.S. declined significantly from 2010 to 2019, according to data published in Health Affairs Scholar.